202 related articles for article (PubMed ID: 27211268)
1. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Etchin J; Berezovskaya A; Conway AS; Galinsky IA; Stone RM; Baloglu E; Senapedis W; Landesman Y; Kauffman M; Shacham S; Wang JC; Look AT
Leukemia; 2017 Jan; 31(1):143-150. PubMed ID: 27211268
[TBL] [Abstract][Full Text] [Related]
2. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
Etchin J; Sun Q; Kentsis A; Farmer A; Zhang ZC; Sanda T; Mansour MR; Barcelo C; McCauley D; Kauffman M; Shacham S; Christie AL; Kung AL; Rodig SJ; Chook YM; Look AT
Leukemia; 2013 Jan; 27(1):66-74. PubMed ID: 22847027
[TBL] [Abstract][Full Text] [Related]
3. P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
Lin KH; Rutter JC; Xie A; Killarney ST; Vaganay C; Benaksas C; Ling F; Sodaro G; Meslin PA; Bassil CF; Fenouille N; Hoj J; Washart R; Ang HX; Cerda-Smith C; Chaintreuil P; Jacquel A; Auberger P; Forget A; Itzykson R; Lu M; Lin J; Pierobon M; Sheng Z; Li X; Chilkoti A; Owzar K; Rizzieri DA; Pardee TS; Benajiba L; Petricoin E; Puissant A; Wood KC
Nat Cancer; 2022 Jul; 3(7):837-851. PubMed ID: 35668193
[TBL] [Abstract][Full Text] [Related]
4. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
5. SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents.
Gerecitano J
J Hematol Oncol; 2014 Oct; 7():67. PubMed ID: 25281264
[TBL] [Abstract][Full Text] [Related]
6. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
London CA; Bernabe LF; Barnard S; Kisseberth WC; Borgatti A; Henson M; Wilson H; Jensen K; Ito D; Modiano JF; Bear MD; Pennell ML; Saint-Martin JR; McCauley D; Kauffman M; Shacham S
PLoS One; 2014; 9(2):e87585. PubMed ID: 24503695
[TBL] [Abstract][Full Text] [Related]
8. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.
Abdul Razak AR; Mau-Soerensen M; Gabrail NY; Gerecitano JF; Shields AF; Unger TJ; Saint-Martin JR; Carlson R; Landesman Y; McCauley D; Rashal T; Lassen U; Kim R; Stayner LA; Mirza MR; Kauffman M; Shacham S; Mahipal A
J Clin Oncol; 2016 Dec; 34(34):4142-4150. PubMed ID: 26926685
[TBL] [Abstract][Full Text] [Related]
9. Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.
Mittal K; Cooper GW; Lee BP; Su Y; Skinner KT; Shim J; Jonus HC; Kim WJ; Doshi M; Almanza D; Kynnap BD; Christie AL; Yang X; Cowley GS; Leeper BA; Morton CL; Dwivedi B; Lawrence T; Rupji M; Keskula P; Meyer S; Clinton CM; Bhasin M; Crompton BD; Tseng YY; Boehm JS; Ligon KL; Root DE; Murphy AJ; Weinstock DM; Gokhale PC; Spangle JM; Rivera MN; Mullen EA; Stegmaier K; Goldsmith KC; Hahn WC; Hong AL
Commun Biol; 2024 Apr; 7(1):426. PubMed ID: 38589567
[TBL] [Abstract][Full Text] [Related]
10. Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors.
Jing CB; Prutsch N; He S; Zimmerman MW; Landesman Y; Look AT
Br J Haematol; 2023 May; 201(3):489-501. PubMed ID: 36746437
[TBL] [Abstract][Full Text] [Related]
11. Selinexor in multiple myeloma.
Martino EA; Vigna E; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Torricelli F; Neri A; Morabito F; Gentile M
Expert Opin Pharmacother; 2024 Mar; 25(4):421-434. PubMed ID: 38503547
[TBL] [Abstract][Full Text] [Related]
12. XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.
Cai X; Liu Y; Li H; Que Y; Xiao M; Wang Y; Wang X; Li D
Ann Hematol; 2024 Mar; ():. PubMed ID: 38519605
[TBL] [Abstract][Full Text] [Related]
13. Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer.
He Y; Mei J; Hao H; Liu F; Yi Y; Hu C; Zou F; Lu X
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6931-6941. PubMed ID: 36840755
[TBL] [Abstract][Full Text] [Related]
14. XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.
Marullo R; Rutherford SC; Revuelta MV; Zamponi N; Culjkovic-Kraljacic B; Kotlov N; Di Siervi N; Lara-Garcia J; Allan JN; Ruan J; Furman RR; Chen Z; Shore TB; Phillips AA; Mayer S; Hsu J; van Besien K; Leonard JP; Borden KLB; Inghirami G; Martin P; Cerchietti L
Cancer Res; 2024 Jan; 84(1):101-117. PubMed ID: 37801604
[TBL] [Abstract][Full Text] [Related]
15. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
Fisher JG; Doyle ADP; Graham LV; Sonar S; Sale B; Henderson I; Del Rio L; Johnson PWM; Landesman Y; Cragg MS; Forconi F; Walker CJ; Khakoo SI; Blunt MD
Leukemia; 2023 Oct; 37(10):2036-2049. PubMed ID: 37528310
[TBL] [Abstract][Full Text] [Related]
16. In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals.
Widman DG; Gornisiewicz S; Shacham S; Tamir S
PLoS One; 2018; 13(10):e0200043. PubMed ID: 30332435
[TBL] [Abstract][Full Text] [Related]
17. CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia.
Farge T; Nakhle J; Lagarde D; Cognet G; Polley N; Castellano R; Nicolau ML; Bosc C; Sabatier M; Sahal A; Saland E; Jeanson Y; Guiraud N; Boet E; Bergoglio C; Gotanègre M; Mouchel PL; Stuani L; Larrue C; Sallese M; De Mas V; Moro C; Dray C; Collette Y; Raymond-Letron I; Ader I; Récher C; Sarry JE; Cabon F; Vergez F; Carrière A
Cancer Res; 2023 Sep; 83(17):2824-2838. PubMed ID: 37327406
[TBL] [Abstract][Full Text] [Related]
18. High Throughput Fluorescence-Based In Vitro Experimental Platform for the Identification of Effective Therapies to Overcome Tumour Microenvironment-Mediated Drug Resistance in AML.
Arroyo-Berdugo Y; Sendino M; Greaves D; Nojszewska N; Idilli O; So CW; Di Silvio L; Quartey-Papafio R; Farzaneh F; Rodriguez JA; Calle Y
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046649
[TBL] [Abstract][Full Text] [Related]
19. The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.
Bianchi M; Reichen C; Croset A; Fischer S; Eggenschwiler A; Grübler Y; Marpakwar R; Looser T; Spitzli P; Herzog C; Villemagne D; Schiegg D; Abduli L; Iss C; Neculcea A; Franchini M; Lekishvili T; Ragusa S; Zitt C; Kaufmann Y; Auge A; Hänggi M; Ali W; Frasconi TM; Wullschleger S; Schlegel I; Matzner M; Lüthi U; Schlereth B; Dawson KM; Kirkin V; Ochsenbein AF; Grimm S; Reschke N; Riether C; Steiner D; Leupin N; Goubier A
Cancer Immunol Res; 2024 Apr; ():. PubMed ID: 38683145
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting of Exportin-1 in Childhood Cancer.
Galinski B; Alexander TB; Mitchell DA; Chatwin HV; Awah C; Green AL; Weiser DA
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
